Cynthia Epperson
Concepts (567)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premenstrual Syndrome | 18 | 2023 | 33 | 4.770 |
Why?
| | Pregnancy Complications | 21 | 2018 | 606 | 3.610 |
Why?
| | Depression, Postpartum | 18 | 2022 | 117 | 3.520 |
Why?
| | Stress, Psychological | 16 | 2026 | 1174 | 3.460 |
Why?
| | Premenstrual Dysphoric Disorder | 13 | 2024 | 17 | 3.280 |
Why?
| | Mental Disorders | 15 | 2026 | 1188 | 2.920 |
Why?
| | Menopause | 13 | 2023 | 328 | 2.920 |
Why?
| | Sex Characteristics | 14 | 2024 | 799 | 2.740 |
Why?
| | Depression | 21 | 2026 | 1599 | 2.020 |
Why?
| | Gonadal Steroid Hormones | 6 | 2018 | 143 | 1.820 |
Why?
| | Mood Disorders | 7 | 2020 | 145 | 1.790 |
Why?
| | Brain | 22 | 2024 | 3009 | 1.780 |
Why?
| | Executive Function | 9 | 2024 | 472 | 1.780 |
Why?
| | Lisdexamfetamine Dimesylate | 3 | 2024 | 8 | 1.780 |
Why?
| | Mental Health | 6 | 2026 | 813 | 1.730 |
Why?
| | gamma-Aminobutyric Acid | 11 | 2023 | 195 | 1.720 |
Why?
| | Biomedical Research | 4 | 2026 | 723 | 1.720 |
Why?
| | Female | 150 | 2026 | 80076 | 1.660 |
Why?
| | Perimenopause | 5 | 2026 | 69 | 1.640 |
Why?
| | Emigrants and Immigrants | 3 | 2026 | 160 | 1.620 |
Why?
| | Prefrontal Cortex | 7 | 2019 | 342 | 1.570 |
Why?
| | Sex Factors | 17 | 2026 | 2136 | 1.540 |
Why?
| | Depressive Disorder | 8 | 2017 | 379 | 1.500 |
Why?
| | Cross-Over Studies | 10 | 2024 | 617 | 1.500 |
Why?
| | Reflex, Startle | 3 | 2022 | 75 | 1.480 |
Why?
| | Hydrocortisone | 5 | 2024 | 300 | 1.460 |
Why?
| | Child Abuse | 4 | 2025 | 558 | 1.410 |
Why?
| | Antidepressive Agents | 13 | 2024 | 245 | 1.380 |
Why?
| | Humans | 168 | 2026 | 147293 | 1.320 |
Why?
| | Prenatal Exposure Delayed Effects | 5 | 2019 | 663 | 1.300 |
Why?
| | Hypothalamo-Hypophyseal System | 8 | 2024 | 201 | 1.270 |
Why?
| | Menstrual Cycle | 10 | 2025 | 145 | 1.270 |
Why?
| | Serotonin | 9 | 2024 | 300 | 1.260 |
Why?
| | Resilience, Psychological | 2 | 2025 | 157 | 1.260 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2022 | 185 | 1.260 |
Why?
| | Anxiety | 13 | 2026 | 1149 | 1.210 |
Why?
| | Sleep Initiation and Maintenance Disorders | 2 | 2023 | 198 | 1.200 |
Why?
| | Memory, Short-Term | 6 | 2020 | 271 | 1.200 |
Why?
| | Cognition | 9 | 2023 | 1286 | 1.180 |
Why?
| | Stress, Physiological | 5 | 2024 | 445 | 1.160 |
Why?
| | Pregnancy | 38 | 2025 | 7274 | 1.150 |
Why?
| | Tryptophan | 7 | 2020 | 183 | 1.120 |
Why?
| | Pituitary-Adrenal System | 6 | 2024 | 166 | 1.090 |
Why?
| | Adult | 79 | 2026 | 41405 | 1.050 |
Why?
| | Stress Disorders, Post-Traumatic | 6 | 2026 | 902 | 1.010 |
Why?
| | Salpingo-oophorectomy | 2 | 2024 | 19 | 0.990 |
Why?
| | Central Nervous System Stimulants | 3 | 2024 | 187 | 0.990 |
Why?
| | Lower Urinary Tract Symptoms | 4 | 2020 | 62 | 0.990 |
Why?
| | Psychotherapy | 8 | 2018 | 184 | 0.980 |
Why?
| | Estradiol | 12 | 2023 | 515 | 0.950 |
Why?
| | War Exposure | 1 | 2026 | 15 | 0.950 |
Why?
| | Literacy | 1 | 2026 | 13 | 0.930 |
Why?
| | Progesterone | 9 | 2023 | 215 | 0.930 |
Why?
| | Psychiatry | 2 | 2026 | 197 | 0.920 |
Why?
| | Longevity | 2 | 2019 | 178 | 0.920 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2025 | 34 | 0.880 |
Why?
| | Postmenopause | 4 | 2023 | 394 | 0.880 |
Why?
| | Pregnanolone | 7 | 2023 | 34 | 0.880 |
Why?
| | Smoking Cessation | 4 | 2022 | 441 | 0.880 |
Why?
| | Sertraline | 6 | 2024 | 28 | 0.870 |
Why?
| | Transgender Persons | 2 | 2018 | 214 | 0.850 |
Why?
| | Transcranial Magnetic Stimulation | 2 | 2018 | 67 | 0.840 |
Why?
| | Double-Blind Method | 15 | 2024 | 2080 | 0.820 |
Why?
| | Refugees | 1 | 2025 | 84 | 0.800 |
Why?
| | Smartphone | 1 | 2025 | 107 | 0.800 |
Why?
| | Glutamic Acid | 6 | 2024 | 256 | 0.790 |
Why?
| | Mothers | 4 | 2024 | 774 | 0.790 |
Why?
| | C-Reactive Protein | 2 | 2023 | 430 | 0.780 |
Why?
| | Psychiatric Status Rating Scales | 12 | 2022 | 537 | 0.780 |
Why?
| | Saliva | 2 | 2024 | 252 | 0.770 |
Why?
| | Urinalysis | 1 | 2023 | 83 | 0.750 |
Why?
| | Gender Identity | 3 | 2018 | 133 | 0.750 |
Why?
| | Middle Aged | 46 | 2026 | 36821 | 0.750 |
Why?
| | Ethics Committees, Research | 2 | 2020 | 41 | 0.740 |
Why?
| | Positron-Emission Tomography | 3 | 2020 | 344 | 0.730 |
Why?
| | Nicotine | 4 | 2024 | 336 | 0.730 |
Why?
| | Emotions | 6 | 2023 | 583 | 0.720 |
Why?
| | Magnetic Resonance Imaging | 12 | 2024 | 3980 | 0.720 |
Why?
| | Obsessive-Compulsive Disorder | 8 | 2010 | 61 | 0.720 |
Why?
| | Fellowships and Scholarships | 1 | 2026 | 357 | 0.700 |
Why?
| | Psychopharmacology | 1 | 2021 | 7 | 0.690 |
Why?
| | Transsexualism | 2 | 2018 | 21 | 0.680 |
Why?
| | Prenatal Diagnosis | 1 | 2023 | 196 | 0.680 |
Why?
| | Health Services Accessibility | 3 | 2025 | 1121 | 0.660 |
Why?
| | Education, Medical, Graduate | 1 | 2026 | 568 | 0.650 |
Why?
| | Estrogens | 4 | 2020 | 368 | 0.640 |
Why?
| | Tobacco Use Disorder | 1 | 2022 | 217 | 0.640 |
Why?
| | Affect | 6 | 2023 | 323 | 0.640 |
Why?
| | Therapy, Computer-Assisted | 3 | 2017 | 63 | 0.630 |
Why?
| | Male | 52 | 2026 | 73950 | 0.620 |
Why?
| | Young Adult | 24 | 2026 | 14437 | 0.620 |
Why?
| | Cognition Disorders | 3 | 2017 | 551 | 0.620 |
Why?
| | Smoking | 5 | 2022 | 1483 | 0.620 |
Why?
| | Luteal Phase | 6 | 2024 | 51 | 0.610 |
Why?
| | Life Change Events | 3 | 2017 | 149 | 0.600 |
Why?
| | Attention | 2 | 2015 | 464 | 0.600 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 6 | 2015 | 232 | 0.590 |
Why?
| | Health Resources | 1 | 2020 | 132 | 0.580 |
Why?
| | Spermatozoa | 3 | 2026 | 109 | 0.570 |
Why?
| | Surveys and Questionnaires | 14 | 2025 | 6164 | 0.570 |
Why?
| | Interdisciplinary Research | 1 | 2019 | 26 | 0.570 |
Why?
| | Sleep Wake Disorders | 1 | 2023 | 315 | 0.560 |
Why?
| | Curriculum | 1 | 2026 | 1082 | 0.560 |
Why?
| | Acoustic Stimulation | 2 | 2018 | 334 | 0.550 |
Why?
| | Ovarian Neoplasms | 2 | 2024 | 599 | 0.540 |
Why?
| | Healthcare Disparities | 1 | 2025 | 740 | 0.540 |
Why?
| | Cost of Illness | 1 | 2020 | 327 | 0.530 |
Why?
| | Patient Dropouts | 1 | 2018 | 67 | 0.510 |
Why?
| | Immune System | 1 | 2018 | 181 | 0.500 |
Why?
| | Puerperal Disorders | 2 | 2010 | 36 | 0.500 |
Why?
| | Urinary Bladder, Overactive | 2 | 2019 | 23 | 0.500 |
Why?
| | Inflammation | 4 | 2024 | 2920 | 0.490 |
Why?
| | Premature Birth | 4 | 2017 | 390 | 0.480 |
Why?
| | National Institutes of Health (U.S.) | 3 | 2024 | 149 | 0.460 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 627 | 0.450 |
Why?
| | beta-Cyclodextrins | 3 | 2022 | 32 | 0.450 |
Why?
| | Adolescent | 20 | 2025 | 22825 | 0.450 |
Why?
| | Cigarette Smoking | 1 | 2017 | 103 | 0.440 |
Why?
| | Occipital Lobe | 5 | 2006 | 30 | 0.440 |
Why?
| | Internship and Residency | 1 | 2026 | 1279 | 0.440 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2014 | 155 | 0.430 |
Why?
| | Dementia | 2 | 2016 | 332 | 0.420 |
Why?
| | Monoamine Oxidase | 1 | 2014 | 27 | 0.420 |
Why?
| | Postpartum Period | 6 | 2022 | 379 | 0.420 |
Why?
| | Research Design | 4 | 2024 | 1157 | 0.420 |
Why?
| | Treatment Outcome | 22 | 2022 | 11947 | 0.410 |
Why?
| | Cytokines | 2 | 2019 | 2086 | 0.410 |
Why?
| | Outpatients | 1 | 2018 | 450 | 0.410 |
Why?
| | United States | 14 | 2026 | 16313 | 0.410 |
Why?
| | RNA, Small Untranslated | 2 | 2026 | 14 | 0.400 |
Why?
| | Platelet Aggregation | 1 | 2014 | 99 | 0.400 |
Why?
| | Bipolar Disorder | 3 | 2011 | 307 | 0.400 |
Why?
| | Patient Compliance | 1 | 2018 | 591 | 0.390 |
Why?
| | Antipsychotic Agents | 4 | 2006 | 211 | 0.390 |
Why?
| | Neuroimaging | 5 | 2024 | 309 | 0.390 |
Why?
| | Quality of Life | 5 | 2026 | 3246 | 0.380 |
Why?
| | Patient Acceptance of Health Care | 3 | 2017 | 895 | 0.380 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2013 | 38 | 0.380 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 587 | 0.380 |
Why?
| | Memory | 2 | 2013 | 300 | 0.370 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2018 | 794 | 0.370 |
Why?
| | Estrus | 1 | 2012 | 16 | 0.370 |
Why?
| | Neurotransmitter Agents | 2 | 2018 | 84 | 0.370 |
Why?
| | Libido | 2 | 2023 | 24 | 0.370 |
Why?
| | Cyclohexanecarboxylic Acids | 1 | 2012 | 19 | 0.360 |
Why?
| | Sexual Maturation | 1 | 2012 | 48 | 0.360 |
Why?
| | Seasonal Affective Disorder | 2 | 2011 | 9 | 0.360 |
Why?
| | Amines | 1 | 2012 | 40 | 0.360 |
Why?
| | Socioeconomic Factors | 5 | 2026 | 1342 | 0.360 |
Why?
| | Longitudinal Studies | 6 | 2026 | 3027 | 0.350 |
Why?
| | Steroids | 2 | 2018 | 162 | 0.350 |
Why?
| | Smokers | 2 | 2022 | 139 | 0.350 |
Why?
| | Propylamines | 1 | 2011 | 11 | 0.340 |
Why?
| | Adrenergic Uptake Inhibitors | 1 | 2011 | 14 | 0.340 |
Why?
| | Neuropsychological Tests | 7 | 2020 | 1145 | 0.340 |
Why?
| | White Matter | 2 | 2024 | 170 | 0.330 |
Why?
| | Fluoxetine | 5 | 2006 | 57 | 0.320 |
Why?
| | Women's Health | 4 | 2026 | 317 | 0.320 |
Why?
| | Self Concept | 2 | 2025 | 259 | 0.320 |
Why?
| | Reproductive History | 1 | 2010 | 12 | 0.320 |
Why?
| | Blood Platelets | 2 | 2004 | 381 | 0.320 |
Why?
| | Gastrointestinal Microbiome | 1 | 2018 | 773 | 0.320 |
Why?
| | Aging | 4 | 2026 | 1992 | 0.310 |
Why?
| | Trichotillomania | 3 | 1999 | 5 | 0.300 |
Why?
| | Memory Disorders | 1 | 2011 | 198 | 0.300 |
Why?
| | Pregnanes | 2 | 2006 | 2 | 0.300 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 506 | 0.300 |
Why?
| | Animals | 15 | 2024 | 38410 | 0.290 |
Why?
| | Behavior, Animal | 1 | 2012 | 530 | 0.290 |
Why?
| | Naltrexone | 1 | 2010 | 115 | 0.280 |
Why?
| | Child | 10 | 2025 | 22979 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 2223 | 0.270 |
Why?
| | Narcotic Antagonists | 1 | 2010 | 210 | 0.270 |
Why?
| | Hormone Replacement Therapy | 2 | 2018 | 109 | 0.270 |
Why?
| | Anxiety Disorders | 3 | 2021 | 376 | 0.260 |
Why?
| | Oxygen | 1 | 2013 | 998 | 0.260 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 959 | 0.260 |
Why?
| | Prevalence | 7 | 2022 | 2889 | 0.250 |
Why?
| | Interleukin-6 | 2 | 2023 | 784 | 0.250 |
Why?
| | Phototherapy | 2 | 2004 | 50 | 0.240 |
Why?
| | Breast Feeding | 4 | 2014 | 447 | 0.240 |
Why?
| | Reproducibility of Results | 5 | 2021 | 3448 | 0.240 |
Why?
| | Lebanon | 1 | 2026 | 3 | 0.240 |
Why?
| | Pilot Projects | 6 | 2024 | 1912 | 0.240 |
Why?
| | Telemedicine | 3 | 2025 | 978 | 0.240 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2023 | 1224 | 0.240 |
Why?
| | Intergenerational Relations | 1 | 2026 | 20 | 0.240 |
Why?
| | Oxytocin | 2 | 1996 | 51 | 0.230 |
Why?
| | Mental Health Services | 2 | 2025 | 478 | 0.230 |
Why?
| | Prolactin | 1 | 2006 | 88 | 0.230 |
Why?
| | Drug Combinations | 3 | 2022 | 399 | 0.230 |
Why?
| | Self Report | 3 | 2020 | 887 | 0.220 |
Why?
| | Abortion, Legal | 1 | 2025 | 28 | 0.220 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2018 | 145 | 0.220 |
Why?
| | Risk Factors | 8 | 2019 | 11017 | 0.220 |
Why?
| | Maternal Behavior | 2 | 2016 | 84 | 0.210 |
Why?
| | Risperidone | 3 | 2000 | 30 | 0.210 |
Why?
| | Puberty | 1 | 2006 | 137 | 0.210 |
Why?
| | Sperm Motility | 1 | 2024 | 37 | 0.210 |
Why?
| | Gestational Age | 2 | 2023 | 997 | 0.210 |
Why?
| | Latin America | 1 | 2024 | 96 | 0.200 |
Why?
| | Career Mobility | 1 | 2024 | 68 | 0.200 |
Why?
| | Neuronal Plasticity | 2 | 2024 | 311 | 0.200 |
Why?
| | Cross-Sectional Studies | 6 | 2023 | 6011 | 0.200 |
Why?
| | Mexico | 1 | 2024 | 233 | 0.200 |
Why?
| | Awards and Prizes | 1 | 2024 | 72 | 0.200 |
Why?
| | Nocturia | 2 | 2020 | 8 | 0.200 |
Why?
| | Gene Regulatory Networks | 1 | 2026 | 318 | 0.200 |
Why?
| | Ovary | 1 | 2025 | 236 | 0.190 |
Why?
| | Medicaid | 2 | 2018 | 475 | 0.190 |
Why?
| | Abortion, Induced | 1 | 2025 | 113 | 0.190 |
Why?
| | HIV Infections | 1 | 2019 | 3235 | 0.190 |
Why?
| | Prenatal Care | 2 | 2017 | 310 | 0.190 |
Why?
| | Epilepsy | 1 | 2008 | 399 | 0.190 |
Why?
| | Mother-Child Relations | 1 | 2024 | 131 | 0.190 |
Why?
| | Aged | 12 | 2020 | 26514 | 0.190 |
Why?
| | Pirenzepine | 2 | 1999 | 8 | 0.190 |
Why?
| | Acoustics | 1 | 2022 | 48 | 0.180 |
Why?
| | Maternal Exposure | 1 | 2004 | 190 | 0.180 |
Why?
| | Serotonin Antagonists | 3 | 2000 | 32 | 0.180 |
Why?
| | Medically Unexplained Symptoms | 1 | 2022 | 5 | 0.180 |
Why?
| | Premenopause | 1 | 2023 | 129 | 0.180 |
Why?
| | Cohort Studies | 6 | 2024 | 6099 | 0.180 |
Why?
| | Health Status | 2 | 2020 | 839 | 0.180 |
Why?
| | Hospitalization | 1 | 2013 | 2496 | 0.180 |
Why?
| | Comorbidity | 6 | 2018 | 1672 | 0.180 |
Why?
| | Urination | 1 | 2022 | 47 | 0.170 |
Why?
| | Sexual Behavior | 2 | 2023 | 502 | 0.170 |
Why?
| | Administration, Cutaneous | 3 | 2011 | 127 | 0.170 |
Why?
| | Milk, Human | 1 | 2003 | 176 | 0.170 |
Why?
| | Contraceptive Agents | 1 | 2022 | 66 | 0.170 |
Why?
| | Health Priorities | 1 | 2021 | 44 | 0.170 |
Why?
| | Sex Offenses | 1 | 2024 | 199 | 0.170 |
Why?
| | Faculty, Medical | 1 | 2024 | 308 | 0.160 |
Why?
| | Norpregnadienes | 1 | 2020 | 3 | 0.160 |
Why?
| | Urinary Bladder | 2 | 2020 | 198 | 0.160 |
Why?
| | Pennsylvania | 2 | 2018 | 138 | 0.160 |
Why?
| | Reward | 1 | 2023 | 248 | 0.160 |
Why?
| | Animal Care Committees | 1 | 2020 | 5 | 0.160 |
Why?
| | Epigenesis, Genetic | 3 | 2020 | 708 | 0.150 |
Why?
| | Fatigue | 1 | 2022 | 367 | 0.150 |
Why?
| | Cues | 1 | 2022 | 329 | 0.150 |
Why?
| | BRCA2 Protein | 1 | 2020 | 68 | 0.150 |
Why?
| | BRCA1 Protein | 1 | 2020 | 83 | 0.150 |
Why?
| | Contraception | 1 | 2022 | 170 | 0.150 |
Why?
| | Nerve Net | 2 | 2020 | 288 | 0.150 |
Why?
| | Ovariectomy | 1 | 2020 | 166 | 0.150 |
Why?
| | Hypogonadism | 1 | 2020 | 93 | 0.150 |
Why?
| | Sex Distribution | 1 | 2020 | 390 | 0.150 |
Why?
| | Menstruation | 2 | 2012 | 44 | 0.150 |
Why?
| | Administration, Oral | 2 | 2012 | 874 | 0.140 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 208 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2018 | 5476 | 0.140 |
Why?
| | Infant | 5 | 2024 | 10194 | 0.140 |
Why?
| | Cerebral Cortex | 1 | 2002 | 483 | 0.140 |
Why?
| | GABA Agonists | 1 | 2018 | 24 | 0.140 |
Why?
| | Receptors, GABA | 1 | 2018 | 13 | 0.140 |
Why?
| | History, 20th Century | 1 | 2020 | 333 | 0.140 |
Why?
| | Protons | 2 | 2012 | 96 | 0.140 |
Why?
| | Gender Dysphoria | 1 | 2018 | 19 | 0.140 |
Why?
| | Occupations | 1 | 2018 | 51 | 0.140 |
Why?
| | Psychophysiology | 1 | 2018 | 12 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 272 | 0.140 |
Why?
| | Neurobiology | 1 | 2018 | 14 | 0.140 |
Why?
| | 1-Naphthylamine | 2 | 1997 | 2 | 0.140 |
Why?
| | N-Acetylglucosaminyltransferases | 1 | 2018 | 24 | 0.140 |
Why?
| | Fetus | 1 | 2023 | 805 | 0.140 |
Why?
| | Benzodiazepines | 3 | 2014 | 169 | 0.140 |
Why?
| | Propensity Score | 1 | 2020 | 379 | 0.140 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2018 | 97 | 0.140 |
Why?
| | Cause of Death | 1 | 2020 | 475 | 0.130 |
Why?
| | Pandemics | 2 | 2024 | 1720 | 0.130 |
Why?
| | Obstetric Labor Complications | 1 | 2017 | 38 | 0.130 |
Why?
| | Mitochondria | 1 | 2024 | 1000 | 0.130 |
Why?
| | Glutamine | 2 | 2016 | 110 | 0.130 |
Why?
| | Melatonin | 2 | 2011 | 164 | 0.130 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 185 | 0.130 |
Why?
| | Ecosystem | 1 | 2021 | 483 | 0.130 |
Why?
| | Monitoring, Ambulatory | 1 | 2017 | 89 | 0.120 |
Why?
| | Child of Impaired Parents | 1 | 2017 | 38 | 0.120 |
Why?
| | Population Surveillance | 1 | 2020 | 486 | 0.120 |
Why?
| | Health Care Costs | 1 | 2020 | 428 | 0.120 |
Why?
| | Sleep | 1 | 2024 | 895 | 0.120 |
Why?
| | Family Conflict | 1 | 2017 | 43 | 0.120 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2016 | 4 | 0.120 |
Why?
| | Domestic Violence | 1 | 2017 | 51 | 0.120 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2016 | 15 | 0.120 |
Why?
| | Functional Neuroimaging | 2 | 2019 | 62 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2018 | 394 | 0.120 |
Why?
| | Child Abuse, Sexual | 1 | 2017 | 81 | 0.120 |
Why?
| | Cross-Cultural Comparison | 1 | 2016 | 84 | 0.120 |
Why?
| | Radionuclide Imaging | 1 | 2016 | 116 | 0.120 |
Why?
| | Perinatal Care | 1 | 2017 | 61 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2018 | 512 | 0.120 |
Why?
| | Adrenal Glands | 1 | 2016 | 77 | 0.120 |
Why?
| | Carcinoma, Renal Cell | 1 | 2019 | 233 | 0.120 |
Why?
| | Patient Care Management | 1 | 2016 | 56 | 0.120 |
Why?
| | Precision Medicine | 1 | 2020 | 464 | 0.120 |
Why?
| | Standard of Care | 1 | 2016 | 81 | 0.110 |
Why?
| | Physicians | 1 | 2024 | 961 | 0.110 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2018 | 190 | 0.110 |
Why?
| | Feces | 1 | 2018 | 500 | 0.110 |
Why?
| | Infant, Newborn | 6 | 2014 | 6543 | 0.110 |
Why?
| | Data Collection | 2 | 2024 | 652 | 0.110 |
Why?
| | Placebos | 2 | 2013 | 193 | 0.110 |
Why?
| | Mobile Applications | 1 | 2017 | 199 | 0.110 |
Why?
| | Brain Mapping | 4 | 2020 | 550 | 0.110 |
Why?
| | Astronauts | 1 | 2014 | 29 | 0.110 |
Why?
| | Fear | 1 | 2018 | 373 | 0.110 |
Why?
| | Patient Preference | 1 | 2017 | 225 | 0.110 |
Why?
| | Behavioral Research | 1 | 2014 | 34 | 0.100 |
Why?
| | Fetal Development | 2 | 2018 | 298 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2022 | 17560 | 0.100 |
Why?
| | Testosterone | 1 | 2018 | 417 | 0.100 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 421 | 0.100 |
Why?
| | Ultrasonography, Prenatal | 1 | 2016 | 295 | 0.100 |
Why?
| | Obesity | 2 | 2018 | 3149 | 0.100 |
Why?
| | Space Flight | 1 | 2014 | 72 | 0.100 |
Why?
| | Transcriptome | 1 | 2020 | 1059 | 0.100 |
Why?
| | Poverty | 1 | 2018 | 533 | 0.100 |
Why?
| | Drug Therapy, Combination | 5 | 2006 | 1046 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2017 | 1147 | 0.100 |
Why?
| | Gyrus Cinguli | 1 | 2014 | 99 | 0.100 |
Why?
| | Ultrasonography, Doppler | 1 | 2014 | 126 | 0.100 |
Why?
| | Urban Population | 1 | 2017 | 502 | 0.100 |
Why?
| | Anisotropy | 2 | 2024 | 78 | 0.100 |
Why?
| | Mental Recall | 1 | 2015 | 225 | 0.100 |
Why?
| | Psychotherapy, Brief | 1 | 2013 | 41 | 0.100 |
Why?
| | Behavior | 2 | 2020 | 90 | 0.100 |
Why?
| | Patient Satisfaction | 2 | 2014 | 718 | 0.090 |
Why?
| | Acute Disease | 2 | 2020 | 1049 | 0.090 |
Why?
| | Rodentia | 1 | 2013 | 62 | 0.090 |
Why?
| | Brain Chemistry | 2 | 2007 | 121 | 0.090 |
Why?
| | Diffusion Tensor Imaging | 2 | 2024 | 83 | 0.090 |
Why?
| | Brachial Artery | 1 | 2014 | 209 | 0.090 |
Why?
| | Frontal Lobe | 1 | 2014 | 161 | 0.090 |
Why?
| | Histones | 1 | 2018 | 672 | 0.090 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 422 | 0.090 |
Why?
| | Infant, Low Birth Weight | 1 | 2013 | 156 | 0.090 |
Why?
| | Weight Loss | 1 | 2018 | 867 | 0.090 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2973 | 0.090 |
Why?
| | Circadian Rhythm | 3 | 2014 | 514 | 0.090 |
Why?
| | Heart Rate | 1 | 2016 | 860 | 0.090 |
Why?
| | Atomoxetine Hydrochloride | 1 | 2011 | 8 | 0.090 |
Why?
| | Delirium | 1 | 2013 | 106 | 0.090 |
Why?
| | Placenta | 1 | 2018 | 793 | 0.080 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 653 | 0.080 |
Why?
| | Disease Management | 1 | 2015 | 654 | 0.080 |
Why?
| | Prescription Drugs | 1 | 2013 | 111 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1518 | 0.080 |
Why?
| | Patients | 1 | 2013 | 184 | 0.080 |
Why?
| | Body Weight | 2 | 2018 | 976 | 0.080 |
Why?
| | Peripartum Period | 1 | 2011 | 19 | 0.080 |
Why?
| | Projection | 1 | 2010 | 3 | 0.080 |
Why?
| | Pregnancy, High-Risk | 1 | 2010 | 13 | 0.080 |
Why?
| | Psychoanalytic Therapy | 1 | 2010 | 13 | 0.080 |
Why?
| | Electron Transport Chain Complex Proteins | 1 | 2010 | 20 | 0.080 |
Why?
| | Vasodilation | 1 | 2014 | 522 | 0.080 |
Why?
| | Diet | 1 | 2018 | 1284 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2010 | 781 | 0.080 |
Why?
| | Psychomotor Performance | 2 | 2011 | 326 | 0.080 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 736 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2016 | 3660 | 0.080 |
Why?
| | Object Attachment | 1 | 2010 | 48 | 0.080 |
Why?
| | Apoptotic Protease-Activating Factor 1 | 1 | 2010 | 2 | 0.080 |
Why?
| | Alzheimer Disease | 1 | 2016 | 639 | 0.080 |
Why?
| | Menarche | 1 | 2010 | 53 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2012 | 253 | 0.080 |
Why?
| | Boston | 2 | 2020 | 93 | 0.080 |
Why?
| | Parturition | 1 | 2010 | 73 | 0.070 |
Why?
| | Professional-Patient Relations | 1 | 2010 | 149 | 0.070 |
Why?
| | Nitric Oxide | 1 | 2014 | 892 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4604 | 0.070 |
Why?
| | Fluvoxamine | 3 | 1999 | 18 | 0.070 |
Why?
| | Antimanic Agents | 1 | 2009 | 19 | 0.070 |
Why?
| | Follicular Phase | 2 | 2014 | 41 | 0.070 |
Why?
| | Seasons | 1 | 2011 | 540 | 0.070 |
Why?
| | Mutation | 1 | 2020 | 4130 | 0.070 |
Why?
| | Estrogen Replacement Therapy | 2 | 2015 | 144 | 0.070 |
Why?
| | Triazines | 1 | 2009 | 49 | 0.070 |
Why?
| | Age of Onset | 1 | 2010 | 568 | 0.070 |
Why?
| | Alleles | 2 | 2010 | 909 | 0.070 |
Why?
| | Logistic Models | 1 | 2013 | 2142 | 0.070 |
Why?
| | Time Factors | 3 | 2018 | 7173 | 0.070 |
Why?
| | Recurrence | 2 | 2013 | 1151 | 0.070 |
Why?
| | Odds Ratio | 1 | 2010 | 1084 | 0.070 |
Why?
| | Aspartic Acid | 2 | 2005 | 88 | 0.070 |
Why?
| | Azetidines | 1 | 2007 | 45 | 0.060 |
Why?
| | Fetal Growth Retardation | 1 | 2013 | 594 | 0.060 |
Why?
| | Amino Acids | 1 | 2011 | 519 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 1195 | 0.060 |
Why?
| | Critical Care | 1 | 2013 | 705 | 0.060 |
Why?
| | Aged, 80 and over | 3 | 2020 | 8430 | 0.060 |
Why?
| | Administration, Intranasal | 2 | 1996 | 94 | 0.060 |
Why?
| | Gonadal Disorders | 1 | 2006 | 1 | 0.060 |
Why?
| | Arousal | 1 | 2007 | 158 | 0.060 |
Why?
| | Interviews as Topic | 1 | 2010 | 932 | 0.060 |
Why?
| | Dehydroepiandrosterone | 1 | 2006 | 49 | 0.060 |
Why?
| | Verbal Learning | 1 | 2006 | 73 | 0.060 |
Why?
| | Medication Adherence | 1 | 2010 | 540 | 0.060 |
Why?
| | Photic Stimulation | 1 | 2007 | 266 | 0.060 |
Why?
| | Hormones | 1 | 2006 | 136 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1072 | 0.060 |
Why?
| | Receptors, Nicotinic | 1 | 2007 | 328 | 0.050 |
Why?
| | Semen Analysis | 1 | 2024 | 15 | 0.050 |
Why?
| | Epididymis | 1 | 2024 | 14 | 0.050 |
Why?
| | Health Surveys | 2 | 2019 | 522 | 0.050 |
Why?
| | Cotinine | 1 | 2005 | 77 | 0.050 |
Why?
| | Cell Respiration | 1 | 2024 | 105 | 0.050 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1794 | 0.050 |
Why?
| | Limbic System | 1 | 2024 | 55 | 0.050 |
Why?
| | Androsterone | 1 | 2023 | 2 | 0.050 |
Why?
| | Visual Perception | 1 | 2006 | 184 | 0.050 |
Why?
| | Electronics | 1 | 2024 | 65 | 0.050 |
Why?
| | Suicidal Ideation | 2 | 2022 | 590 | 0.050 |
Why?
| | Ketanserin | 1 | 2003 | 12 | 0.050 |
Why?
| | Receptors, Serotonin | 1 | 2003 | 34 | 0.050 |
Why?
| | Half-Life | 1 | 2003 | 157 | 0.050 |
Why?
| | Statistics as Topic | 1 | 2004 | 285 | 0.050 |
Why?
| | Technology | 1 | 2024 | 99 | 0.050 |
Why?
| | Chronic Disease | 2 | 2020 | 1844 | 0.050 |
Why?
| | Vulnerable Populations | 1 | 2024 | 177 | 0.050 |
Why?
| | Pyridines | 1 | 2007 | 610 | 0.050 |
Why?
| | Facial Expression | 1 | 2023 | 75 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2679 | 0.050 |
Why?
| | Heterosexuality | 1 | 2023 | 49 | 0.050 |
Why?
| | Biomarkers | 2 | 2024 | 4351 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1598 | 0.040 |
Why?
| | Fetal Blood | 1 | 2004 | 327 | 0.040 |
Why?
| | GABA-A Receptor Antagonists | 1 | 2021 | 19 | 0.040 |
Why?
| | Washington | 1 | 2022 | 157 | 0.040 |
Why?
| | Extracellular Vesicles | 1 | 2024 | 175 | 0.040 |
Why?
| | Child, Preschool | 1 | 2017 | 12016 | 0.040 |
Why?
| | Synaptic Transmission | 2 | 2020 | 293 | 0.040 |
Why?
| | Biology | 1 | 2022 | 89 | 0.040 |
Why?
| | Gray Matter | 1 | 2022 | 97 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2020 | 90 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2019 | 789 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 6041 | 0.040 |
Why?
| | alpha-Methyltyrosine | 1 | 1999 | 2 | 0.040 |
Why?
| | Preliminary Data | 1 | 2019 | 12 | 0.040 |
Why?
| | Dysuria | 1 | 2019 | 3 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 484 | 0.040 |
Why?
| | RNA, Transfer | 1 | 2020 | 143 | 0.040 |
Why?
| | Teaching Materials | 1 | 1999 | 22 | 0.040 |
Why?
| | Catecholamines | 1 | 1999 | 88 | 0.040 |
Why?
| | Independent Living | 1 | 2020 | 116 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2020 | 244 | 0.040 |
Why?
| | Urinary Incontinence | 1 | 2019 | 65 | 0.040 |
Why?
| | Alcoholism | 1 | 2005 | 838 | 0.030 |
Why?
| | Genes, X-Linked | 1 | 2018 | 21 | 0.030 |
Why?
| | Risk Assessment | 3 | 2019 | 3784 | 0.030 |
Why?
| | Philadelphia | 1 | 2018 | 55 | 0.030 |
Why?
| | Personality Inventory | 2 | 2013 | 134 | 0.030 |
Why?
| | Mice | 3 | 2024 | 18491 | 0.030 |
Why?
| | Restraint, Physical | 1 | 2018 | 76 | 0.030 |
Why?
| | Neural Pathways | 1 | 2020 | 320 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 2018 | 198 | 0.030 |
Why?
| | Drug Resistance | 1 | 1999 | 145 | 0.030 |
Why?
| | Histone Code | 1 | 2018 | 39 | 0.030 |
Why?
| | Pregnancy Trimester, Third | 1 | 2018 | 119 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 643 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 443 | 0.030 |
Why?
| | Control Groups | 1 | 2017 | 12 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2024 | 1141 | 0.030 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2014 | 62 | 0.030 |
Why?
| | Reproduction | 1 | 1999 | 212 | 0.030 |
Why?
| | Obstetric Labor, Premature | 1 | 2017 | 39 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1999 | 347 | 0.030 |
Why?
| | Embryo, Mammalian | 1 | 2018 | 234 | 0.030 |
Why?
| | Genetic Linkage | 1 | 1998 | 273 | 0.030 |
Why?
| | Placebo Effect | 1 | 2017 | 24 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2019 | 429 | 0.030 |
Why?
| | Anhedonia | 1 | 2017 | 18 | 0.030 |
Why?
| | Health Personnel | 1 | 2024 | 762 | 0.030 |
Why?
| | Patient Health Questionnaire | 1 | 2017 | 44 | 0.030 |
Why?
| | Membrane Transport Proteins | 1 | 1998 | 154 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 779 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2006 | 1112 | 0.030 |
Why?
| | Pulse | 1 | 1996 | 29 | 0.030 |
Why?
| | Paraventricular Hypothalamic Nucleus | 1 | 2016 | 34 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2018 | 221 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 975 | 0.030 |
Why?
| | Public Health | 1 | 2021 | 577 | 0.030 |
Why?
| | Workplace | 1 | 2018 | 272 | 0.030 |
Why?
| | Factor Analysis, Statistical | 1 | 2017 | 296 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2017 | 430 | 0.030 |
Why?
| | Reference Standards | 1 | 2016 | 177 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 822 | 0.030 |
Why?
| | Trophoblasts | 1 | 2018 | 219 | 0.030 |
Why?
| | International Cooperation | 1 | 2016 | 198 | 0.030 |
Why?
| | Observer Variation | 1 | 2016 | 358 | 0.030 |
Why?
| | Organ Size | 1 | 2016 | 465 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1386 | 0.030 |
Why?
| | Corticosterone | 1 | 2016 | 241 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 499 | 0.030 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.030 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1344 | 0.030 |
Why?
| | Connecticut | 1 | 2014 | 25 | 0.030 |
Why?
| | Hot Flashes | 1 | 2015 | 92 | 0.030 |
Why?
| | Aerospace Medicine | 1 | 2014 | 32 | 0.030 |
Why?
| | Weightlessness | 1 | 2014 | 40 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2030 | 0.030 |
Why?
| | Nerve Tissue Proteins | 1 | 1998 | 597 | 0.030 |
Why?
| | Ambulatory Care | 1 | 1999 | 625 | 0.030 |
Why?
| | MicroRNAs | 1 | 2020 | 694 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1998 | 731 | 0.030 |
Why?
| | Choline | 2 | 2005 | 138 | 0.030 |
Why?
| | Genotyping Techniques | 1 | 2014 | 72 | 0.030 |
Why?
| | Massachusetts | 1 | 2014 | 181 | 0.030 |
Why?
| | Parity | 1 | 2014 | 112 | 0.020 |
Why?
| | Multimedia | 1 | 2013 | 13 | 0.020 |
Why?
| | San Francisco | 1 | 2013 | 60 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2014 | 203 | 0.020 |
Why?
| | Suicide, Attempted | 1 | 2017 | 430 | 0.020 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2014 | 153 | 0.020 |
Why?
| | Genotype | 2 | 2014 | 1875 | 0.020 |
Why?
| | Group Processes | 1 | 2013 | 63 | 0.020 |
Why?
| | Attitude | 1 | 2014 | 260 | 0.020 |
Why?
| | Age Factors | 1 | 2019 | 3372 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 567 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4383 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2014 | 586 | 0.020 |
Why?
| | Population Groups | 1 | 2010 | 56 | 0.020 |
Why?
| | Blood Pressure | 1 | 1996 | 1785 | 0.020 |
Why?
| | Social Support | 1 | 2014 | 655 | 0.020 |
Why?
| | Psychometrics | 1 | 2013 | 739 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 505 | 0.020 |
Why?
| | Dopamine Antagonists | 2 | 2000 | 26 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2010 | 751 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 980 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 3216 | 0.020 |
Why?
| | Down-Regulation | 1 | 2010 | 618 | 0.020 |
Why?
| | Internet | 1 | 2013 | 696 | 0.020 |
Why?
| | Mass Screening | 1 | 2017 | 1375 | 0.020 |
Why?
| | Up-Regulation | 1 | 2010 | 848 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1776 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2231 | 0.020 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 104 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2007 | 335 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2007 | 210 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2175 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2020 | 2627 | 0.010 |
Why?
| | Creatine | 1 | 2005 | 63 | 0.010 |
Why?
| | Prospective Studies | 1 | 2017 | 8164 | 0.010 |
Why?
| | Fluorine Radioisotopes | 1 | 2003 | 14 | 0.010 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2003 | 18 | 0.010 |
Why?
| | Tomography, Emission-Computed | 1 | 2003 | 71 | 0.010 |
Why?
| | Pyramidal Cells | 1 | 2003 | 81 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2010 | 2812 | 0.010 |
Why?
| | Tics | 1 | 2000 | 6 | 0.010 |
Why?
| | Schizotypal Personality Disorder | 1 | 2000 | 11 | 0.010 |
Why?
| | Models, Neurological | 1 | 2002 | 253 | 0.010 |
Why?
| | Treatment Failure | 1 | 1999 | 360 | 0.010 |
Why?
| | Clomipramine | 1 | 1996 | 2 | 0.010 |
Why?
| | Buspirone | 1 | 1996 | 5 | 0.010 |
Why?
| | Clonazepam | 1 | 1996 | 4 | 0.010 |
Why?
| | Paroxetine | 1 | 1996 | 9 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1302 | 0.010 |
Why?
| | Lithium | 1 | 1996 | 40 | 0.010 |
Why?
| | Fenfluramine | 1 | 1996 | 20 | 0.010 |
Why?
| | Drug Tolerance | 1 | 1996 | 99 | 0.010 |
Why?
| | Costs and Cost Analysis | 1 | 1996 | 221 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1998 | 615 | 0.010 |
Why?
| | Drug Interactions | 1 | 1996 | 405 | 0.010 |
Why?
|
|
Epperson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|